Biocept (BIOC) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares.
View BIOC analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1-year price objectives for Biocept's stock. Their BIOC share price forecasts range from $120.00 to $120.00. On average, they anticipate the company's share price to reach $120.00 in the next year. This suggests a possible upside of 6,122.5% from the stock's current price.
View analysts price targets for BIOC or view top-rated stocks among Wall Street analysts.

Biocept's stock was trading at $15.90 at the beginning of 2023. Since then, BIOC stock has decreased by 87.9% and is now trading at $1.9285.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BIOC earnings forecast.

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.90 EPS for the quarter, missing the consensus estimate of $2.70 by $1.80. The medical research company earned $17.47 million during the quarter, compared to analyst estimates of $16.87 million. Biocept had a negative trailing twelve-month return on equity of 235.66% and a negative net margin of 32.99%. During the same period in the previous year, the business posted ($12.90) EPS.

Biocept shares reverse split before market open on Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Biocept's stock is owned by a variety of institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include David F Hale and David F Hale.
View institutional ownership trends.

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOC stock can currently be purchased for approximately $1.93.

Biocept (NASDAQ:BIOC) has a market capitalization of $1.14 million and generates $25.86 million in revenue each year. The medical research company earns $-32,090,000.00 in net income (profit) each year or ($64.2642) on an earnings per share basis.

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.